No Data
Guggenheim Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $810
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): 'Arguably The Most Innovative Biopharma Company I've Seen In The Last Two Decades'
Regeneron Pharmaceuticals (NasdaqGS:REGN) To Showcase Oncology And Respiratory Data At Major Conferences
Regeneron Pharma Is Maintained at Buy by Guggenheim
Regeneron Pharma To Present New And Updated Data From Oncology And Hematology Portfolio At ASCO Annual Meeting
Express News | Regeneron to Highlight Advances at Asco With Phase 3 Adjuvant Libtayo® (Cemiplimab) Cscc Updates and Promising Early Blood Cancer Data With Linvoseltamab Combination
skumaar42 : Great info!